Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

esigned to evaluate the efficacy and safety of VCP in relapsed / refractory MM patients. The study included 13 evaluable patients, who received VELCADE at 1.5 mg/m2 on days 1, 8 and 15 of a 28-day schedule. Patients also received 300 mg/m2 of cyclophosphamide on days 1, 8, 15 and 22 and prednisone at 100 mg every two days. Patients were treated for up to eight cycles. Response was assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria. Results were presented by Dr. Reece and showed an ORR (CR + partial response + minor response) of 93 percent, including a high CR rate of 54 percent. At one year, all patients were alive (one-year survival rate). Therapy demonstrated excellent patient tolerance with side effects similar to those seen with each agent alone.

Phase II Study of VELCADE, Lenalidomide and Dexamethasone in Relapsed / Refractory Multiple Myeloma (Abstract #PO-660)

The Phase II multi-center study evaluated the efficacy and safety of this novel combination therapy. The trial included 19 evaluable relapsed / refractory MM patients, including those who had received prior VELCADE, lenalidomide, thalidomide or stem cell transplantation. The patients received VELCADE at 1.0 mg/m2 on days 1, 4, 8 and 11 of a 21-day schedule; lenalidomide at 15 mg on days 1 through 14; and dexamethasone at 40 mg for cycles one through four and 20 mg for cycles five through eight. Patients received a median of five cycles. Responses were assessed using the EBMT criteria. Results were presented by Paul Richardson, M.D., Dana-Farber Cancer Institute, and showed a 68 percent ORR, including a CR rate of 5 percent. Therapy was well tolerated with no grade 3 or higher toxicities.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... 2014 Recently, iFitDress.com, one of the most ... one shoulder evening gown collection. According to the ... at discounted rates (up to 69% off) at present. Additionally, ... , “I am a frequent caller of your site. ... my dress, I feel quite happy. All items are of ...
(Date:9/16/2014)... 16, 2014 The second federal bellwether ... & Johnson subsidiary Ethicon concluded with the jury in ... and awarding her $3.27 million in damages, according to ... report, “jurors found Ethicon liable for selling faulty devices ... users were at risk from side effects that include ...
(Date:9/16/2014)... forensic techniques are shedding light on a 500-year-old mystery: ... the last English monarch to die in battle? ... whole-body CT scans and micro-CT imaging of injured bones, ... suffered at the Battle of Bosworth Field, where he ... revealed that two skull injuries could have killed the ...
(Date:9/16/2014)... Paradigm Physical Therapy is proud to ... treatment for their patients. Dry needling is a procedure ... of musculoskeletal problems. , In this invasive procedure, a ... skin and muscle to create a trigger point. Using ... helps to deactivate and release the trigger point within ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Paradigm Physical Therapy Introduces Dry Needling 2
... cells (CTCs) may be a promising alternative, noninvasive source ... presented at the Fourth AACR International Conference on Molecular ... idea is that CTCs can provide real-time information about ... biopsy," said Siminder Kaur Atwal, Ph.D., senior research associate ...
... study carried out by Spanish researchers has shown that the ... for good or for bad, the way in which work-related ... manifests itself. Noise-related hearing loss is the most common occupational ... presence of metalworking fluids exhibit a delay in hearing alteration ...
... TUESDAY, Sept. 28 (HealthDay News) -- American middle-school students who ... mentally better off than those who don,t, a new study ... explore the potential health impact that team sports activity might ... ages of 12 and 14. "Other studies have looked ...
... By Steven Reinberg HealthDay Reporter , ... comparison of drug-coated stents -- the metal mesh tubes ... model using the drug sirolimus came out on top, ... coated with zotarolimus, fell short, the study found. ...
... discernible influence on how African American patients with asthma ... study. Researchers found that improved lung function in ... series of baseline breathing function measures, not genetic ancestry. ... of Allergy & Clinical Immunology , http://www.aaaai.org/media/jaci/ ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... Pediatrics doesn,t want children exposed to tobacco ads at ... marketing and advertisements for erectile dysfunction drugs and other ... of the recommendations in its new policy statement, "Children, ...
Cached Medicine News:Health News:Circulating tumor cells can provide 'real-time' information on patient's current disease state 2Health News:Noise and chemicals: Workers are losing their hearing 2Health News:Team Sports Pep Up Middle-School Kids 2Health News:Team Sports Pep Up Middle-School Kids 3Health News:In Test of Stents, Old Standby Wins Out 2Health News:No link between genetic ancestry, asthma response in African-Americans 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 3
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: